|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
Globocan estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Untch M, Konecny GE, Paepke S and von
Minckwitz G: Current and future role of neoadjuvant therapy for
breast cancer. Breast. 23:526–537. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Santa-Maria CA, Camp M, Cimino-Mathews A,
Harvey S, Wright J and Stearns V: Neoadjuvant therapy for
early-stage breast cancer: Current practice, controversies, and
future directions. Oncology (Williston Park). 29:828–838.
2015.PubMed/NCBI
|
|
4
|
Kaufmann M, von Minckwitz G, Bear HD,
Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W,
Jackesz R, et al: Recommendations from an international expert
panel on the use of neoadjuvant (primary) systemic treatment of
operable breast cancer: New perspectives 2006. Ann Oncol.
18:1927–1934. 2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Li X, Dai D, Chen B, Tang H and Wei W:
Oncological outcome of complete response after neoadjuvant
chemotherapy for breast conserving surgery: A systematic review and
meta-analysis. World J Surg Oncol. 15(210)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wang-Lopez Q, Chalabi N, Abrial C,
Radosevic-Robin N, Durando X, Mouret-Reynier MA, Benmammar KE,
Kullab S, Bahadoor M, Chollet P, et al: Can pathologic complete
response (pCR) be used as a surrogate marker of survival after
neoadjuvant therapy for breast cancer? Crit Rev Oncol Hematol.
95:88–104. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Boughey JC, Ballman KV, McCall LM,
Mittendorf EA, Symmans WF, Julian TB, Byrd D and Hunt KK: Tumor
biology and response to chemotherapy impact breast cancer-specific
survival in node-positive breast cancer patients treated with
neoadjuvant chemotherapy: Long-Term follow-up from ACOSOG Z1071
(Alliance). Ann Surg. 266:667–676. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bossuyt V, Provenzano E, Symmans WF,
Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner
G, Kuehn T, et al: Recommendations for standardized pathological
characterization of residual disease for neoadjuvant clinical
trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol.
26:1280–1291. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Templeton AJ, Ace O, McNamara MG,
Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A,
Tannock IF and Amir E: Prognostic role of platelet to lymphocyte
ratio in solid tumors: A systematic review and meta-analysis.
Cancer Epidemiol Biomarkers Prev. 23:1204–1212. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Asano Y, Kashiwagi S, Onoda N, Noda S,
Kawajiri H, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K:
Platelet-Lymphocyte ratio as a useful predictor of the therapeutic
effect of neoadjuvant chemotherapy in breast cancer. PLoS One.
11(e153459)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Graziano V, Grassadonia A, Iezzi L, Vici
P, Pizzuti L, Barba M, Quinzii A, Camplese A, Di Marino P, Peri M,
et al: Combination of peripheral neutrophil-to-lymphocyte ratio and
platelet-to-lymphocyte ratio is predictive of pathological complete
response after neoadjuvant chemotherapy in breast cancer patients.
Breast. 44:33–38. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Asano Y, Kashiwagi S, Onoda N, Noda S,
Kawajiri H, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K:
Predictive value of neutrophil/lymphocyte ratio for efficacy of
preoperative chemotherapy in triple-negative breast cancer. Ann
Surg Oncol. 23:1104–1110. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cserni G, Chmielik E, Cserni B and Tot T:
The new tnm-based staging of breast cancer. Virchows Arch.
472:697–703. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pennisi A, Kieber-Emmons T, Makhoul I and
Hutchins L: Relevance of pathological complete response after
neoadjuvant therapy for breast cancer. Breast Cancer (Auckl).
10:103–106. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yang G, Liu P, Zheng L and Zeng J: Novel
peripheral blood parameters as predictors of neoadjuvant
chemotherapy response in breast cancer. Front Surg.
9(1004687)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lou C, Jin F, Zhao Q and Qi H: Correlation
of Serum NLR, PLR and HALP with efficacy of neoadjuvant
chemotherapy and prognosis of triple-negative breast cancer. Am J
Transl Res. 14:3240–3246. 2022.PubMed/NCBI
|
|
18
|
Jin X, Wang K, Shao X and Huang J:
Prognostic implications of the peripheral platelet-to-lymphocyte
ratio and neutrophil-to-lymphocyte ratio in predicting pathologic
complete response after neoadjuvant chemotherapy in breast cancer
patients. Gland Surg. 11:1057–1066. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
DeNardo DG and Coussens LM: Inflammation
and breast cancer. Balancing immune response: Crosstalk between
adaptive and innate immune cells during breast cancer progression.
Breast Cancer Res. 9(212)2007.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Jenne CN and Kubes P: Platelets in
Inflammation and Infection. Platelets. 26:286–292. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Carestia A, Godin LC and Jenne CN: Step up
to the platelet: Role of platelets in inflammation and infection.
Thromb Res: Oct 14, 2022 (Epub ahead of print).
|
|
24
|
Klinger MH and Jelkmann W: Role of blood
platelets in infection and inflammation. J Interferon Cytokine Res.
22:913–922. 2002.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Dunn GP, Old LJ and Schreiber RD: The
Immunobiology of cancer immunosurveillance and immunoediting.
Immunity. 21:137–148. 2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH,
Lee HE, Kim YJ, Kim JH and Park SY: Tumour-Infiltrating Cd8+
lymphocytes as an independent predictive factor for pathological
complete response to primary systemic therapy in breast cancer. Br
J Cancer. 109:2705–2713. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ibrahim EM, Al-Foheidi ME, Al-Mansour MM
and Kazkaz GA: The prognostic value of tumor-infiltrating
lymphocytes in triple-negative breast cancer: A meta-analysis.
Breast Cancer Res Treat. 148:467–476. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Denkert C, von Minckwitz G, Darb-Esfahani
S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen
F, Furlanetto J, et al: Tumour-Infiltrating lymphocytes and
prognosis in different subtypes of breast cancer: A pooled analysis
of 3771 patients treated with neoadjuvant therapy. Lancet Oncol.
19:40–50. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Paramanathan A, Saxena A and Morris DL: A
systematic review and meta-analysis on the impact of pre-operative
neutrophil lymphocyte ratio on long term outcomes after curative
intent resection of solid tumours. Surg Oncol. 23:31–39.
2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhang M, Huang XZ, Song YX, Gao P, Sun JX
and Wang ZN: High platelet-to-lymphocyte ratio predicts poor
prognosis and clinicopathological characteristics in patients with
breast cancer: A meta-analysis. Biomed Res Int.
2017(9503025)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Templeton AJ, McNamara MG, Seruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106(dju 124)2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ethier JL, Desautels D, Templeton A, Shah
PS and Amir E: Prognostic role of neutrophil-to-lymphocyte ratio in
breast cancer: A systematic review and meta-analysis. Breast Cancer
Res. 19(2)2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wei B, Yao M, Xing C, Wang W, Yao J, Hong
Y, Liu Y and Fu P: The neutrophil lymphocyte ratio is associated
with breast cancer prognosis: An updated systematic review and
meta-analysis. Onco Targets Ther. 9:5567–5575. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang F, Liu ZY, Xia YY, Zhou C, Shen XM,
Li XL, Han SG, Zheng Y, Mao ZQ, Gong FR, et al: Changes in
neutrophil/lymphocyte and platelet/lymphocyte ratios after
chemotherapy correlate with chemotherapy response and prediction of
prognosis in patients with unresectable gastric cancer. Oncol Lett.
10:3411–3418. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hyder J, Boggs DH, Hanna A, Suntharalingam
M and Chuong MD: Changes in neutrophil-to-lymphocyte and
platelet-to-lymphocyte ratios during chemoradiation predict for
survival and pathologic complete response in trimodality esophageal
cancer patients. J Gastrointest Oncol. 7:189–195. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tankel J, Calderone A, Garcia-Luna J,
Mueller CL, Najmeh S, Spicer J, Mulder D, Ferri L and
Cools-Lartigue J: Changes in perioperative platelet lymphocyte
ratio predict survival in oesophago-gastric adenocarcinoma. Ann
Surg Oncol: Apr 4, 2022 (Epub ahead of print).
|
|
37
|
Li Z, Zhao R, Cui Y, Zhou Y and Wu X: The
dynamic change of neutrophil to lymphocyte ratio can predict
clinical outcome in stage I-III colon cancer. Sci Rep.
8(9453)2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kaufmann M, Hortobagyi GN, Goldhirsch A,
Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R,
Jonat W, et al: Recommendations from an international expert panel
on the use of neoadjuvant (primary) systemic treatment of operable
breast cancer: An update. J Clin Oncol. 24:1940–1949.
2006.PubMed/NCBI View Article : Google Scholar
|
